Use of aspirin among diabetics in the primary prevention of cardiovascular disease: Need for reliable randomized evidence and astute clinical judgment

Journal of General Internal Medicine

Volumn 24, Issue 11, 2009, Pages 1248-1250

  Hebert, Patricia R ^a   Schneider, Wendy R ^a   Hennekens, Charles H ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Diabetes; Evidenced based medicine; Prevention; Risk assessment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; PLACEBO; SIMVASTATIN;

ANGINA PECTORIS; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG INDICATION; EARLY INTERVENTION; FOOT AMPUTATION; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STROKE;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; JUDGMENT; MALE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 70449534916     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-009-1095-5     Document Type: Review

References (16)

1. CH Hennekens JE Buring P Sandercock R Collins R Peto 1989 Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease Circulation 80 4 749 756 1:STN:280:DyaK3c%2FgtlKrug%3D%3D 2676237
2. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 7329 71 86 10.1136/bmj.324.7329.71
3. AA Bartolucci G Howard 2006 Meta-analyses of data from six preliminary primary prevention trials of cardiovascular events using aspirin Am J Cardiol 98 6 746 750 10.1016/j.amjcard.2006.04.012 1:CAS:528:DC%2BD28Xptlyrsrs%3D 16950176 (Pubitemid 44301007)
4. TA Pearson SN Blair SR Daniels RH Eckel JM Fair SP Fortmann, et al. 2002 AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases Circulation 106 3 388 391 10.1161/01.CIR.0000020190.45892.75 12119259 (Pubitemid 34778969)
5. US Preventive Services Task Force 2009 Aspirin for the prevention of cardiovascular disease: US preventive services task force recommendation statement Ann Intern Med 150 396 404
6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel or ATP III) 2001 Executive summary of the third report of the National Cholesterol Education Program (NCEP III) JAMA 285 19 2486 2497 10.1001/jama.285.19.2486
7. American Diabetes Association 2004 Aspirin therapy in diabetes (Position Statement) Diabetes Care 27 Suppl 1 S72 S73
8. H Ogawa M Nakayama T Morimoto S Uemura M Kanauchi N Doi for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators, et al. 2008 Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 18 2134 2141 10.1001/jama.2008.623 1:CAS:528:DC%2BD1cXhtlOrtLnM 18997198
9. J Belch A MacCuish I Campbell S Cobbe R Taylor R Prescott Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh, et al. 2008 The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripherial arterial disease BMJ 337 a1840 10.1136/bmj.a1840 18927173
10. JE Manson DE Grobbee MJ Stampfer JO Taylor SZ Goldhaber M Gaziano, et al. 1990 Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians Am J Med 89 6 772 776 10.1016/0002-9343(90)90220-8 1:STN:280:DyaK3M%2FmvVOmsQ%3D%3D 2252045
11. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown and Company; 1987.
12. Early Treatment in Diabetic Retinopathy Study report 14 1992 Aspirin effects on mortality and morbidity in patients with diabetes mellitus JAMA 268 10 1292 1300 10.1001/jama.268.10.1292
13. A Study of Cardiovascular Events in Diabetes (ASCEND). University of Oxford, Clinical Trial Service Unit Website. Available from: http://www.ctsu.ox.ac.uk/ascend/. Accessed December 3, 2008.
14. G De Berardis M Sacco V Evangelista ACCEPT-D Study Group, et al. 2007 Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 8 21 29 10.1186/1745-6215-8-21 17725825 (Pubitemid 47570624)
15. CH Hennekens D Hollar C Baigent 2006 Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis Nat Clin Pract Cardiovasc Med 3 1 1 3 10.1038/ncpcardio0420 (Pubitemid 43078203)
16. DB Rolka A Fagot-Campagna KM Narayan 2001 Aspirin use among adults with diabetes. Estimates from the third national health and nutrition examination survey Diabetes Care 24 2 197 201 10.2337/diacare.24.2.197 1:STN:280: DC%2BD3M7nvF2qsA%3D%3D 11213865